Medical Instruments & Supplies
(ABMD) Abiomed Releases Encouraging Preliminary Fourth Quarter Data
Leading cardiac assist devices maker, Abiomed Inc. (ABMD), provided encouraging preliminary data for its fourth-quarter 2013 results. The company will report full results on May 2, 2013. Revenues climbed 17% year over year...3May2013 | vitalstocks | Comments Off | Continued
(COV) Covidien plc Rolls Out More Concerta Drugs
Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), launched more dosages of the Concerta (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII). The company introduced the new 36 mg and 54 mg dosage strengths. In...11Apr2013 | vitalstocks | Comments Off | Continued
(VVUS) Vivus’ Qsiva Sees Negative Decision From European Medicines Agency
Vivus, Inc. (VVUS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) re-examined and confirmed its decision about not recommending the approval of weight-loss...25Feb2013 | Shawn | Comments Off | Continued
(BDX) Becton, Dickinson and Company Beats Again – Guides Higher
Medical technology major Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2013 earnings per share from continuing operations of $1.35, reflecting a beat of 9.8% over the Zacks Consensus Estimate. The company...7Feb2013 | Shawn | Comments Off | Continued
(HAE) Haemonetics – Bull of the Day
2013 is considered a landmark year for Haemonetics (HAE) based on several key growth factors, including entry in the $1.2 billion whole blood collection market with the acquisition of the transfusion medicine business of Pall Corp. We are also...14Jan2013 | Shawn | Comments Off | Continued
(MR) Mindray Medical International Limited Downgraded to Neutral
We downgrade our recommendation on Mindray Medical International Limited (MR) to Neutral. Its third-quarter 2012 adjusted (excluding one-time expenses other than stock-based compensation expense) earnings per share of 39 cents missed...6Jan2013 | Shawn | Comments Off | Continued
(COV) Covidien Drug Wins U.S. Food and Drug Administration Approval
Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), has won the U.S. Food and Drug Administration (FDA) approval to manufacture and sell a generic version of CONCERTA (methylphenidate HCl) Extended-Release (ER) Tablets...3Jan2013 | Shawn | Comments Off | Continued
(COV) Covidien Remains at Neutral
We have reiterated our Neutral recommendation on leading health care products maker, Covidien plc. (COV), with a target price of $60. The company’s adjusted earnings per share (from continuing operations) of $1.02 for the...1Jan2013 | Shawn | Comments Off | Continued
(COV) Covidien plc Presents Positive Study Results
Covidien plc. (COV), a large-cap healthcare products company, has announced the five-year results of the ClosureFAST Long-Term European Multi-Center Study. The study revealed that the ...28Dec2012 | Shawn | Comments Off | Continued
(BSX) Boston Scientific Corporation Initiates Ingevity Trial
Boston Scientific Corporation (BSX) recently commenced a trial for its next-generation Ingevity pacing leads. The first patient was implanted to evaluate the safety, effectiveness and ...27Dec2012 | Shawn | Comments Off | Continued
(THOR) Thoratec Soars to 52-Week High
Shares of Thoratec Corp (THOR) reached a 52-week high of $39.50 on Tuesday, December 11, 2012. The medical device stock continues to edge past resistance levels and soared to another 52-week high. The closing price as of December...17Dec2012 | Shawn | Comments Off | Continued
(THOR) Thoratec Corporation – Bull of the Day
We maintain our recommendation for Thoratec Corp. (THOR) at Outperform. Its earnings per share of $0.44 in the third quarter beat the Zacks Consensus Estimate. The company achieved 27% unit growth for HeartMate II in the third quarter. Thoratec’s...16Dec2012 | Shawn | Comments Off | Continued
(BAX) Baxter Presents Study Outcome
Baxter International (BAX) recently revealed critical Phase I/III study outcomes analyzing the efficacy and safety of BAX 326. This is an investigational recombinant factor IX protein, which is utilized for prophylaxis and therapy...11Dec2012 | Shawn | Comments Off | Continued
(THOR) Thoratec Corporation – Bull of the Day
We maintain our recommendation for Thoratec Corp. (THOR) at Outperform. Its earnings per share of $0.44 in the third quarter beat the Zacks Consensus Estimate. The company achieved 27% unit growth for HeartMate II in the third quarter. Thoratec’s...10Dec2012 | Shawn | Comments Off | Continued
(THOR) Thoratec Authorizes New Share Repurchase
Thoratec Corp. (THOR), a leader in mechanical circulatory assistance devices, recently revealed that its board of directors has approved the repurchase of as much as $150 million of its common stock. The earlier authorization lapsed...3Dec2012 | vitalstocks | Comments Off | Continued
(VVUS) Vivus Misses Third Quarter Estimates
Vivus Inc. (VVUS) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss of 10 cents per share. Higher selling, general and administrative...9Nov2012 | vitalstocks | Comments Off | Continued
(THOR) Thoratec Upgraded to Outperform
We upgrade our recommendation for Thoratec Corp. (THOR) to Outperform. HeartMate II unit sales rose 22% in the six months ending June 30, 2012 wrapping up a robust half year. Heart failure is a terminal degenerative condition...23Oct2012 | vitalstocks | Comments Off | Continued
(OSUR) OraSure Technologies Unveils In-Home HIV test
OraSure Technologies (OSUR), a provider of medical devices and technologies to diagnose critical medical conditions, recently announced the availability of its OraQuick in-home HIV test at retail outlets and online, across the U.S. The...23Oct2012 | vitalstocks | Comments Off | Continued
(THOR) Thoratec Corporation – Bull of the Day
We upgrade our recommendation for Thoratec Corporation (THOR) to Outperform. HeartMate II units rose 22% in the six months ending June 30, 2012 wrapping up a robust half-year. Its competitor, HeartWare, has filed a PMA for a similar...10Oct2012 | vitalstocks | Comments Off | Continued
(IART) Integra LifeSciences Holdings Corporation Exhibits Neuro Product Line
Medical products company, Integra LifeSciences Holdings Corporation (IART) is demonstrating its MAYFIELD Composite Series Cranial Stabilization product line at the Congress of Neurological Surgeons (“CNS”) annual meet...10Oct2012 | vitalstocks | Comments Off | Continued
(MR) Mindray Medical International Limited to Display at CMEF
Chinese medical devices major Mindray Medical International Limited (MR) recently revealed that it will showcase over 90 offerings at the 68th China International Medical Equipment Fair (CMEF) to be held in Sichuan, China during the...9Oct2012 | vitalstocks | Comments Off | Continued
(VVUS) Vivus Expects European Setback
Vivus Inc. (VVUS) recently announced that it expects the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to recommend against the approval of its weight-loss drug, Qsiva, next month. The...9Oct2012 | vitalstocks | Comments Off | Continued
(COO) T-Mobile Appoints New CEO
T-Mobile USA – the fourth largest telecom carrier in the U.S. – recently appointed John Legere as Chief Executive Officer, effective this month. John Legere will succeed the interim CEO Jim Alling, who will return back to his existing role of Chief Operating Officer (COO). T-Mobile’s...23Sep2012 | vitalstocks | Comments Off | Continued
(COV) FDA Clears Covidien’s Exalgo Tablet
Mallinckrodt, the pharmaceuticals business of Covidien plc (COV), recently received the clearance of the U.S. Food and Drug Association (FDA) for the 32 mg strength of its Exalgo (hydromorphone HCI) Extended-Release Tablets (CII)....28Aug2012 | vitalstocks | Comments Off | Continued
(COO) Management Changes at Body Central Corporation
Body Central Corp. (BODY) recently promoted Tom Stoltz to the position of the chief operating officer (COO) as well as the interim chief executive officer (CEO). Stoltz had been serving as the company’s executive vice president,...28Aug2012 | vitalstocks | Comments Off | Continued
(CFN) CareFusion Announces Voluntary Product Recall
Recently, CareFusion (CFN), a medical technology company, announced the voluntary recall of its Alaris Pump Module, Model 8100. The recalled lot was manufactured between October 2011 and February 2012. The product recall was...26Aug2012 | vitalstocks | Comments Off | Continued
(WST) West Pharmaceutical Services Sets Up New Facility in India
West Pharmaceutical Services’ (WST) indirect subsidiary, West Pharmaceutical India Packaging Private Ltd., has commenced the construction of a new compression molding facility in Sri City, India. The facility will be a quantum of...26Aug2012 | vitalstocks | Comments Off | Continued
(COV) Covidien Suffers Slew of Product Recalls
Recently, health care products major Covidien plc. (COV) has been hit by a number of product recalls, the most significant being the voluntary recall of the Duet TRS Universal Straight and Articulating Single-Use Loading Units (SULU)....26Aug2012 | vitalstocks | Comments Off | Continued
(VVUS) Vivus Reports Wider-Than-Expected Loss
Vivus Inc.’s (VVUS) second quarter 2012 loss of 24 cents per share was wider than the Zacks Consensus loss Estimate of 23 cents and the year-ago loss of 20 cents per share. Higher general and administrative (G&A) expenses for...22Aug2012 | vitalstocks | Comments Off | Continued
(PKI) PerkinElmer Remains Neutral
We maintain our Neutral rating on PerkinElmer (PKI) based on its second quarter results. Adjusted earnings per share of 53 cents surpassed the Zacks Consensus Estimate of 48 cents. Net income from continuing operations in the reported...22Aug2012 | vitalstocks | Comments Off | Continued